Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)

Benitec Biopharma has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $190.7 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 141.16% year-over-year to $190.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $386.3 million (up 79.63% YoY) and the FY2025 annual result came in at $99.6 million, up 90.75% from the prior year.
• Liabilities and Shareholders Equity advanced to $190.7 million in Q4 2025 per BNTC's latest filing, from $96.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $190.7 million in Q4 2025 and troughed at $4.5 million in Q2 2023.
• A 5-year average of $40.8 million and a median of $18.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity slumped 72.06% in 2022, then surged 1069.58% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $14.0 million in 2021, then declined by 15.05% to $11.9 million in 2022, then surged by 79.36% to $21.4 million in 2023, then jumped by 270.29% to $79.1 million in 2024, then soared by 141.16% to $190.7 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $190.7 million, $96.0 million, and $99.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.